The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bismuth-212     bismuth

Synonyms: AC1O3RNC, 212Bi, 14913-49-6, Bismuth, isotope of mass 212
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of bismuth


High impact information on bismuth

  • An alpha-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared [3].
  • This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/neuroectodermal surface antigen, Thy 1 [4].
  • In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma [2].

Analytical, diagnostic and therapeutic context of bismuth


  1. Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. Kozak, R.W., Fitzgerald, D.P., Atcher, R.W., Goldman, C.K., Nelson, D.L., Gansow, O.A., Pastan, I., Waldmann, T.A. J. Immunol. (1990) [Pubmed]
  2. In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma. Rotmensch, J., Whitlock, J.L., Schwartz, J.L., Hines, J.J., Reba, R.C., Harper, P.V. Am. J. Obstet. Gynecol. (1997) [Pubmed]
  3. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Macklis, R.M., Kinsey, B.M., Kassis, A.I., Ferrara, J.L., Atcher, R.W., Hines, J.J., Coleman, C.N., Adelstein, S.J., Burakoff, S.J. Science (1988) [Pubmed]
  4. Alpha particle radio-immunotherapy: animal models and clinical prospects. Macklis, R.M., Kaplan, W.D., Ferrara, J.L., Atcher, R.W., Hines, J.J., Burakoff, S.J., Coleman, C.N. Int. J. Radiat. Oncol. Biol. Phys. (1989) [Pubmed]
  5. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Kozak, R.W., Atcher, R.W., Gansow, O.A., Friedman, A.M., Hines, J.J., Waldmann, T.A. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
WikiGenes - Universities